Company
Accord Hlthcare
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
11
4 still marketed
Novel approvals
0
Approvals since 2021
6
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Bortezomib approved Jul 26, 2022
- Pemetrexed Disodium approved Jul 19, 2022
- Carmustine approved May 16, 2022
- Methotrexate new use Mar 10, 2022
- Cabazitaxel approved Dec 29, 2021
- Argatroban In Sodium Chloride approved Jun 7, 2021
- Atropine Sulfate approved Sep 29, 2020
- Methotrexate approved Aug 24, 2020
- Tigecycline approved Jan 18, 2018
- Gemcitabine Hydrochloride approved Aug 3, 2017
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (4)
Newest FDA action first.
- Argatroban In Sodium Chloride Argatroban · 2021
- Atropine Sulfate Atropine Sulfate · 2020
- Docetaxel Docetaxel · 2011
- Paricalcitol Paricalcitol · 2016
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.